Target Name: MEF2B
NCBI ID: G100271849
Review Report on MEF2B Target / Biomarker Content of Review Report on MEF2B Target / Biomarker
Other Name(s): MEF2B_HUMAN | RSRFR2 | serum response factor-like protein 2 | MEF2B variant 1 | myocyte enhancer factor 2B | XMEF2 | LOC729991-MEF2B readthrough | Myocyte-specific enhancer factor 2B | MADS box transcription enhancer factor 2, polypeptide B (myocyte enhancer factor 2B) | Myocyte enhancer factor 2B | Myocyte enhancer factor 2B, transcript variant 1 | Serum response factor-like protein 2 | FLJ32648 | Myocyte-specific enhancer factor 2B (isoform 1) | MEF2BNB-MEF2B readthrough

MEF2B: A Drug Target / Disease Biomarker

MEF2B, also known as mef2b, is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.MEF2B is a gene that encodes a protein known as MEF2B, which is a key regulator of the microtubules that exist in the cells of eukaryotes. Microtubules are important structural elements that help keep cells in shape and are involved in many important cellular processes, including cell division, intracellular transport, and the regulation of gene expression.

The discovery of MEF2B as a potential drug target or biomarker comes from a study by a team of researchers led by Dr. Qin Liu, a professor of chemistry and biochemistry at the University of California, Los Angeles. The researchers identified MEF2B as a gene that is highly expressed in a variety of human tissues and is involved in the development of many diseases, including cancer. They also found that MEF2B is a good candidate for a drug target because it is involved in the regulation of microtubule dynamics and is a known target for several FDA-approved drugs, including taxol and cisapride.

One of the challenges in studying MEF2B as a potential drug target is its complex structure and the fact that it is involved in many different cellular processes. The researchers used a combination of techniques, including RNA interference, live cell imaging, and biochemical assays, to study its function in these processes. They found that MEF2B plays a key role in regulating microtubule dynamics and that it is involved in the regulation of cell division, migration, and the formation of new blood vessels. They also found thatMEF2B is involved in the regulation of the production of new microtubules, which is important for the development of cancer.

Another potential challenge in studying MEF2B as a drug target is its involvement in multiple diseases, which can make it difficult to study its function in a specific context. The researchers focused on studying the function of MEF2B in the context of cancer, neurodegenerative diseases and autoimmune disorders. They found thatMEF2B is involved in the regulation of multiple cellular processes that are important for the development and progression of these diseases.

In conclusion, MEF2B is a gene that has the potential to be a drug target or biomarker for the treatment of various diseases. Its function as a regulator of microtubule dynamics and its involvement in multiple cellular processes make it an attractive target for drug development. Further studies are needed to fully understand its function and its potential as a drug.

Protein Name: Myocyte Enhancer Factor 2B

Functions: Transcriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific genes. Activates transcription via this element. May be involved in muscle-specific and/or growth factor-related transcription

The "MEF2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MEF2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at

More Common Targets

MEF2C | MEF2C-AS1 | MEF2C-AS2 | MEF2D | MEFV | MEG3 | MEG8 | MEG9 | MEGF10 | MEGF11 | MEGF6 | MEGF8 | MEGF9 | MEI1 | MEI4 | MEIG1 | MEIKIN | MEIOB | MEIOC | MEIOSIN | MEIS1 | MEIS1-AS2 | MEIS1-AS3 | MEIS2 | MEIS3 | MEIS3P1 | MEIS3P2 | Melanin | Melanin-concentrating hormone (MCH) receptor | Melanocortin receptor | Melanoma-Associated Antigen | Melatonin receptor | MELK | MELTF | MELTF-AS1 | Membrane-Bound Protein Tyrosine Phosphatases (rPTPs) | Membrane-spanning 4-domains subfamily A member 4A | MEMO1 | MEMO1P1 | MEMO1P4 | MEMO1P5 | MEN1 | MEOX1 | MEOX2 | MEP1A | MEP1AP2 | MEP1AP4 | MEP1B | MEPCE | MEPE | MERTK | MESD | MESP1 | MESP2 | MEST | MESTIT1 | MESTP3 | MESTP4 | MET | Metabotropic glutamate (mGluR) receptor | Metallothionein | METAP1 | METAP1D | METAP2 | Metaxin complex | Methionine adenosyltransferase | Methionine adenosyltransferase II | Methionyl aminopeptidase | Methylcytosine dioxygenase (TET) | METRN | METRNL | METTL1 | METTL13 | METTL14 | METTL15 | METTL15P1 | METTL15P2 | METTL16 | METTL17 | METTL18 | METTL21A | METTL21C | METTL21EP | METTL22 | METTL23 | METTL24 | METTL25 | METTL25B | METTL26 | METTL27 | METTL2A | METTL2B | METTL3 | METTL4 | METTL5 | METTL6 | METTL7A | METTL7B | METTL8 | METTL9